IP Library Granted Patent US 9,532,946
Granted Patent B2
US 9,532,946 · App. 14/082,813 · Granted Jan 3, 2017

Manufacturing of semi-plastic pharmaceutical dosage units

Inventors: Dominique Kluger (Vienna, AT); Carsten Schmidt (Mainz, DE); Albin Hauler (Traiskirchen, AT); David Schroeckenfuchs (Ernstbrunn, AT); Niki Waldron (Piscataway, NJ)
Assignee: Intervet Inc.
A61K9/0056A61K31/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,532,946
App. No.
14/082,813
Granted
Jan 3, 2017
Kind
B2
Abstract

A process for the manufacture of semi-plastic pharmaceutical unit doses using a rotary moulding machine and semi-plastic pharmaceutical dosage units obtained by this process.

Claims (14)

1. A process for the manufacturing of a semi-plastic pharmaceutical dosage unit, wherein the semi-plastic pharmaceutical dosage unit is a soft chewable veterinary pharmaceutical product for oral administration, comprising at least one active pharmaceutical ingredient and a polyethylene glycol forming agent, comprising the steps of:

a) mixing the at least one active pharmaceutical ingredient with a dry and a liquid component to prepare a premix,

b) heating the polyethylene glycol forming agent until melted,

c) mixing the premix and the polyethylene glycol forming agent together to form a dough,

d) feeding the dough into a container connected with a rotary moulding machine; and

e) forming the semi-plastic pharmaceutical dosage unit in the rotary moulding machine,

wherein the liquid component contains an oil; and

wherein the temperature of the dough in step d) is between about 35° C. and about 45° C.

2. The process according to claim 1 wherein the rotary moulding machine comprises forming moulds with concave edges.

3. The process according to claim 1 , wherein all of the ingredients are of a pharmaceutical grade.

4. The process according to claim 1 , wherein the active pharmaceutical ingredient is an antiparasitic.

5. The process according to claim 1 , wherein the active pharmaceutical ingredient is an isoxazoline compound.

6. The process according to claim 5 wherein the active pharmaceutical ingredient is 4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide.

7. The process of claim 1 , wherein the dry component is a starch or starch like material.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2014
From: KLUGER, DOMINIQUE; HAULER, ALBIN; SCHMIDT, CARSTEN; SCHROECKENFUCHS, DAVID; WALDRON, NIKI
To: INTERVET INC.
Reel/Frame 032758/0575 →
Continuity (3)
Provisional Application 61728379 · Nov 20, 2012
Provisional Application 61791385 · Mar 15, 2013
Related Publication 20140141055A1 · May 22, 2014